INSYS Therapeutics Addresses Maryland Attorney General’s Motion
February 09, 2018 11:22 ET
|
Insys Therapeutics, Inc.
PHOENIX, Feb. 09, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology,...
INSYS Therapeutics Addresses New York Attorney General’s Complaint
February 01, 2018 23:00 ET
|
Insys Therapeutics, Inc.
PHOENIX, Feb. 01, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology,...
INSYS Therapeutics Appoints Vaseem Mahboob to Board of Directors
February 01, 2018 09:00 ET
|
Insys Therapeutics, Inc.
PHOENIX, Feb. 01, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology,...
INSYS Therapeutics Adds Two New Executives to Senior Management Team
January 30, 2018 09:00 ET
|
Insys Therapeutics, Inc.
VP of Human Resources, Carol Summersgill; VP of Clinical Development, Dr. Ahmed Elkashef PHOENIX, Jan. 30, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the...
INSYS Therapeutics to Present at J.P. Morgan Healthcare Conference
January 03, 2018 09:00 ET
|
Insys Therapeutics, Inc.
PHOENIX, Jan. 03, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), announced today that Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial...
FDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Cannabidiol (CBD) Oral Solution as Investigational Treatment for Prader-Willi Syndrome
December 26, 2017 08:30 ET
|
Insys Therapeutics, Inc.
PHOENIX, Dec. 26, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the...
INSYS Therapeutics Initiates Phase 2 Clinical Trial of Cannabidiol (CBD) Oral Solution for Treatment of Refractory Childhood Absence Epilepsy in Pediatric Patients
December 19, 2017 08:00 ET
|
Insys Therapeutics, Inc.
PHOENIX, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Can a synthetic formulation of cannabidiol (CBD), one of the main molecules in cannabis, safely help control treatment-resistant “staring” seizures in...
INSYS Therapeutics Starts Proof-of-Concept Study of Epinephrine Nasal Spray for Anaphylaxis
December 07, 2017 09:00 ET
|
Insys Therapeutics, Inc.
PHOENIX, Dec. 07, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), announced today that it has started a proof-of-concept study of two formulations of...
FDA Accepts New Drug Application (NDA) for Buprenorphine Sublingual Spray from INSYS Therapeutics
December 06, 2017 09:37 ET
|
Insys Therapeutics, Inc.
PHOENIX, Dec. 06, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), announced today that its New Drug Application (NDA) for a novel formulation of...
INSYS Therapeutics, Inc. to Participate in the 29th Annual Piper Jaffray Healthcare Conference
November 27, 2017 06:00 ET
|
Insys Therapeutics, Inc.
PHOENIX, Nov. 27, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”) announced today that Saeed Motahari, president and chief executive officer, and Andrew...